#1COPYRIGHT © ABCELLERA Q2 2023 BUSINESS UPDATE AUGUST 3, 2023 AbCellera#2Q2 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA 2 DISCLAIMER This entation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.#3Q2 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA 3 Q2 2023. BUSINESS UPDATE SUMMARY. CONTINUED PROGRESS IN BUILDING ABCELLERA'S HIGH-VALUE PORTFOLIO $823M 177 106 9 in total cash, cash equivalents & marketable securities cumulative programs under contract cumulative partnered programs started molecules in the clinic#4Q2 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA 4 MARKET OPPORTUNITY. AbCellera's end market is antibody medicines. Programs Per Year Therapeutic Antibodies in the Clinic WHY Market Size in 2022 Source: Allied Market Research ~$6B Antibody Discovery I Market Size by 2030 Source: IQVIA Commercial Antibody Medicines ~$400B#5Q2 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA 5 AbCellera secures ~$220M in non-dilutive funding to accelerate execution of strategy and bring programs into clinic with high capital efficiency. Lab & Office Construction ~$220M Stronger engine. Allows us to offer highly differentiated end-to-end capabilities to select partners. Discovery & Pre-clinical Development ~$190M Clinical Studies ~$100M Enhanced portfolio. Through the advancement of multiple wholly-owned pre-partnered programs from initiation all the way to Phase 1 clinical trials. Total Project Investments ~$520M#6Q2 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA 6 Government funding drives value in multiple dimensions of AbCellera's business. Funding will allow us to advance more pre-partnered programs, and we believe success in these programs will drive value in multiple dimensions of our business: Develop platform, including establishing integrated manufacturing capabilities. Bring programs to value inflection points. Attract additional and higher-value partner- initiated programs.#7o COPYRIGHT © ABCELLERA Q2 2023 FINANCIALS UPDATE#8FINANCIALS Q2 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA 8 Strong portfolio growth. Total # of Programs Under Contract Total # of Discovery Partners 41 177 Cumulative # of Partnered Program Starts 110 100 90 80 70 60 50 40 30 20 10 O 1 2015 16 17 18 19 20 21 22 106 WITHOUT downstream participation + WITH downstream participation 23 Q2 9 8 7 6 5 4 3 2 1 O Cumulative # of Molecules in the Clinic 2015 16 17 18 19 20 21 22 9 23 Q2 Note: Showing year-end figures, except for most-recent quarter. Historical results are not necessarily indicative of future results.#9FINANCIALS Q2 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA 9 9 molecules in the clinic. MOLECULE bamlanivimab (LY-CoV555) bebtelovimab (LY-CoV1404) TAK-920/DNL919 undisclosed undisclosed NBL-012 NBL-015/FL-301 NBL-020 IVX-01 STAGE Marketed, Emergency Use Authorization (EUA) Marketed, Emergency Use Authorization (EUA) Phase 1 Phase 1 Phase 1 Phase 1 Phase 1 IND/CTA authorized Clinical field study THERAPEUTIC AREA ● ● ● infectious disease: COVID-19 ● infectious disease: COVID-19 neurology: Alzheimer's Disease neuroscience undisclosed dermatology gastrointestinal disease immunology • oncology oncology animal health PARTNER Lilly DENALI teva undisclosed NovaRock BOTHERAPEUTICS Invetx PROGRAM TYPE AbCellera pre-partnered program PARTNERED AbCellera partner-initiated discovery Trianni license AbCellera partner-initiated discovery As of June 30, 2023#10FINANCIALS Q2 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA 10 $10M total revenue, predominantly from discovery activity. Revenue USD ROYALTIES MILESTONES LICENSING RESEARCH FEES $45.9M Q2 2022 $10.1M $9.8M Q2 2023 $0.2M#11FINANCIALS Q2 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA 11 Operating expenses reflect ongoing investments. Operating Expenses USD RESEARCH & DEVELOPMENT $26.7M Q2 2022 +$9.8M $36.5M Q2 2023 SALES & MARKETING $3.1M Q2 2022 +$0.7M $3.8M Q2 2023 GENERAL & ADMIN $14.4M Q2 2022 +$1.1M $15.5M Q2 2023#12FINANCIALS Q2 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA 12 Net loss of $31M; equivalent to ($0.11) per share (basic & diluted). Earnings USD NET EARNINGS -$6.8M Q2 2022 -$30.5M Q2 2023 EARNINGS PER SHARE: BASIC -$0.02 Q2 2022 -$0.11 Q2 2023 EARNINGS PER SHARE: DILUTED -$0.02 Q2 2022 -$0.11 Q2 2023#13FINANCIALS Q2 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA 13 Over 800 million in total cash, equivalents, and marketable securities. Cash Flows USD $915M $500M Marketable Securities $387M Cash & Equivalents $28M* 2022-12-31 ($24M) OPERATING $106M Marketable Securities (net) $78M Other ($184M) INVESTING $OM FINANCING $1M FX $823M $616M Marketable Securities $180M Cash & Equivalents $27M* 2023-06-30 Restricted cash (including restricted cash in other assets)#1414 COPYRIGHT © ABCELLERA Q2 2023 BUSINESS UPDATE YOU THANK AbCellera AbCellera Cellera